Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.
Lianxi SongLiang ZengHuan YanQinqin XuQing XiaJian LeiXiaoyan ChenXiaoping HuZhan WangHong LiuNong YangYong-Chang ZhangPublished in: Communications medicine (2022)
Our study provides clinical evidence on the concordance of PD-L1 TPS scores between clones E1L3N and 22C3. Moreover, the treatment responses to pembrolizumab are also comparable between the PDL1-E1L3N and PDL1-22C3. These findings indicate that E1L3N is a reliable and cost-effective assay and may serve as an alternative to 22C3.